XVII CONGRESSO MINEIRO DE PNEUMOLOGIA E CIRURGIA TORÁCICA e VI CONGRESSO MINEIRO DE PNEUMOLOGIA PEDIÁTRICA
Acesse o site do congresso
1º Dia - 10/10/25
2º Dia - 10/11/25
3º Dia - 10/9/25

Etapa III e IV: dose fixa ou variável ? Voltar

Emilio Pizzichini

Mesa Redonda - Asma - Manejo e Tratamento - Flavio Mendonça Andrade da Silva

Artigo Autor(es) Referência
A cost-utility analysis of single maintenance and reliever (SMART) therapy as compared to step 3 fixed-dose therapy in patients aged 12 years or more with uncontrolled asthma. Rodríguez-Martínez Carlos E, Sossa-Briceño Monica P, Castro-Rodriguez Jose A Pediatric pulmonology. 2024 Oct; doi: 10.1002/ppul.27328. pii: .
Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study. Ind P W, Haughney J, Price D, Rosen J P, Kennelly J Respiratory medicine. 2004 May; 98(May):464-75.
Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. FitzGerald J Mark, Sears Malcolm R, Boulet Louis-Philippe, Becker Allan B, McIvor Andrew R, Ernst Pierre, Smiljanic-Georgijev Natasha M, Lee Joanna S M, Canadian respiratory journal. 10():427-34.
Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis. Beasley Richard, Harrison Tim, Peterson Stefan, Gustafson Per, Hamblin Angus, Bengtsson Thomas, Fagerås Malin JAMA network open. 2022 Mar; 5(Mar):e220615. doi: 10.1001/jamanetworkopen.2022.0615. pii: .
Fixed and adjustable dose asthma action plans based on combination therapy: a pilot study. Holt Shaun, Ryder-Lewis Simon, Masoli Matthew, Weatherall Mark, Beasley Richard Respirology (Carlton, Vic.). 2005 Sep; 10(Sep):497-503.
Flexible asthma therapy. D'Urzo Anthony D, Solanki Vasant Canadian family physician Medecin de famille canadien. 2005 Dec; 51(Dec):1633-4, 1636.
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Bateman Eric D, Harrison Tim W, Quirce Santiago, Reddel Helen K, Buhl Roland, Humbert Marc, Jenkins Christine R, Peterson Stefan, Ostlund Ollie, O'Byrne Paul M, Sears Malcolm R, Eriksson Göran S Respiratory research. 2011 Apr; 12(Apr):38. doi: 10.1186/1465-9921-12-38. pii: .
Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. Rogliani Paola, Cavalli Francesco, Chetta Alfredo, Cazzola Mario, Calzetta Luigino Journal of asthma and allergy. 2022 ; 15():565-577. doi: 10.2147/JAA.S283489. pii: .
Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma. McKinlay Lorna, Williamson Peter A, Short Philip M, Fardon Tom C, Lipworth Brian J British journal of clinical pharmacology. 2011 Jan; 71(Jan):128-31. doi: 10.1111/j.1365-2125.2010.03795.x. pii: .
Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelines. Canonica G Walter, Brightling Christopher The World Allergy Organization journal. 2010 Feb; 3(Feb):31-7. doi: 10.1097/WOX.0b013e3181d27cd8. pii: .
Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients. Carpagnano Giovanna E, Scioscia Giulia, Lacedonia Donato, Stornelli Silvia Romana, Irene Quarato Carla Maria, Soccio Piera, Resta Onofrio, Foschino Barbaro Maria Pia Pulmonary pharmacology & therapeutics. 2019 Dec; 60(Dec):101879. doi: 10.1016/j.pupt.2019.101879. pii: S1094-5539(19)30256-1.
Nenhuma revista foi definida para este congresso.